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INTRODUCTION
Over the past years, progress in cerebral
magnetic resonance imaging (MRI) tech-
nology has increased the possibilities to
quantify MS-related tissue changes, start-
ing from lesion assessment in the white
matter (WM) to the quantification of
microstructural changes of the whole brain
(1). This was expected to give full insight
into the causes of MS patients’ deficits
but despite all achievements, the current
plethora of MRI metrics still provides no
complete explanation for the clinical con-
dition on a group (2) and even less so on an
individual level. However, within the scope
of personalized medicine, this remains an
important goal to better understand and
ultimately minimize the functional impact
of MS-related tissue damage.
In this context, functional cerebral
changes including adaptation and plastic-
ity are strong contributors to the apparent
clinical consequences of MS and are likely
to explain part of the “morphological-
clinical gap” (3), notwithstanding ongo-
ing controversies what patient deficits to
consider and how to assess them. Against
this background, we critically review the
development and current state of tech-
niques to assess gross MS-related mor-
phologic damage and their contribution
to understand the clinical consequences of
MS (disability, and also cognitive problems
and fatigue) and the obvious modulating
roles of cerebral adaptation and plasticity
as unraveled by functional MRI (fMRI).
From existing data, we suggest that it is
unlikely to ever achieve a satisfactory level
of explanation and prediction of an indi-
vidual patient’s condition-based solely on
morphologic information, although such
insights might be better suited to define dis-
ease progression than clinical assessment.
WHITE MATTER DAMAGE IN MS
MS has traditionally been viewed as mul-
tifocal WM disease, and depicting lesions
disseminated throughout the CNS using
conventional MRI has become indispens-
able in early diagnosis and management
(4). However, T2-weighted MRI lacks
pathological specificity (5).
FOCAL WHITE MATTER PATHOLOGY
While the basic features of MS pathology
constitute inflammation, demyelination in
WM and GM, and diffuse neurodegenera-
tion within the entire CNS, the individual
components of the pathological spectrum
vary quantitatively between early relaps-
ing and late progressive MS (6). Moreover,
remyelination of existing lesions may be
extensive in a subset of patients and fail in
others (6). All these components cannot be
sufficiently assessed on T2-weighted MRI.
Compared to T2-hyperintense lesions,
so-called “black holes” (severely and per-
sistent hypointense lesions on T1-weighted
MRI) have been shown to offer a more
specific marker of matrix destruction and
axonal loss (7). However, their definition is
variable and strongly dependent on scan-
ning parameters, which prohibits closer
quantitation.
NON-CONVENTIONAL MRI TO QUANTIFY
LESIONAL WHITE MATTER DAMAGE
A more refined insight into the com-
position of lesions may be gained by
non-conventional techniques like magne-
tization transfer (MT) imaging (MTI),
diffusion-weighted imaging (DWI), and
diffusion tensor imaging (DTI).
MT-ratio (MTR) changes may precede
the formation of active MS lesions by
months, indicating changes in the macro-
molecular composition of pre-lesional
WM long before a lesion becomes visible
on conventional MRI (8). Once a lesion
has formed, i.e., becomes apparent on T2-
weighted MRI, MTI may serve to follow the
evolution and fate of affected parenchyma.
Comparison with histopathology has
shown good correlations with both
demyelination and remyelination, and also
just with fiber or neuronal density (5, 9).
In a longitudinal trial, MTR-changes fol-
lowed different temporal evolutions and
were ongoing in different lesion regions for
at least 3 years after lesion formation (10).
Diffusion-weighted imaging and DTI
yield different insights. Diffusion measures
the microscopic Brownian motion of water
molecules, which is hindered by cellular
structures (e.g., cell membranes and axonal
cytoskeletons). In general, low-fractional
anisotropy (FA) and high-mean diffusiv-
ity (MD) are found in MS lesions, but
values are highly heterogeneous. Unfortu-
nately, few studies investigated pathological
correlates of DWI in MS. Surprisingly,
at post-mortem, MD and FA correlated
more strongly with myelin content than
with axonal count and gliosis in one
study (11).
NON-CONVENTIONAL MRI TO QUANTIFY
DIFFUSE WHITE MATTER DAMAGE
Diffusion-weighted imaging/DTI and MTI
played important roles in shaping the
notion that MS not only consists of focal
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T2-lesions but also affects WM in a more
widespread manner. Thus, normal appear-
ing white matter (NAWM) in MS, in
fact, is not normal, but demonstrates sub-
tle microstructural abnormalities outside
lesions. Histogram analyses have frequently
been used to explore respective MRI met-
rics across the whole brain (12–14). Using
MTI, MS patients consistently showed both
lower average MTR and lower peak height
(15) and respective DTI analyses demon-
strated higher average MD, lower his-
togram peak height MD, and lower average
FA (14, 16) compared to healthy controls,
respectively. Lower FA values close to and
higher values far from MS lesions sug-
gest Wallerian degeneration (17), but MD
and FA of NAWM only partially corre-
late with the extent and severity of focal
lesions, indicating other factors like astro-
cytic hyperplasia, patchy edema, perivascu-
lar infiltration, demyelination, and axonal
loss also contribute to such abnormali-
ties (14).
STRATEGIC LOCATION OF WHITE MATTER
DAMAGE
Assessing the strategic location of WM
damage using lesion probability maps
(LPM) or diffusion-based tractography
(DBT) represents another promising
approach to improve upon morphological-
clinical correlations. Thus, LPM in dif-
ferent MS phenotypes revealed associ-
ations between specific neurologic and
cognitive deficits with lesion accumu-
lation in distinct, anatomically plausi-
ble, regions, but only to limited extent
(18). Using tract-based spatial statis-
tics [TBSS; a fully automated, whole-
brain diffusion analysis method (14)] to
identify loci where reduced WM-tract
FA predicted impaired cognitive perfor-
mance in MS patients, cognitively rel-
evant tract localizations only partially
overlapped with areas of high-lesion prob-
ability, but identified tract localizations
were found to interconnect cortical regions
involved in cognitive processing (19).
Thus, there is evidence that abnormal-
ities in strategic brain WM tracts con-
tribute to cognitive impairment in MS,
but the identified regions vary between
studies and it is unlikely that such analy-
ses could be performed on an individual
level.
GRAY MATTER DAMAGE IN MS
GRAY MATTER PATHOLOGY
Autopsy studies have demonstrated that
MS is also associated with focal lesions in
and diffuse demyelination of GM (20, 21).
The depiction of these kinds of MS-related
damage has been and still is a challenge
for MRI.
FOCAL GRAY MATTER DAMAGE
Intrinsically, low-myelin densities in the
cortex (where demyelination generates
little contrast), the often small size of
lesions, and partial volume effects of cere-
brospinal fluid impede the detection of
cortical GM lesions on conventional MRI
(21). Introduction of the double-inversion
recovery (DIR) sequence with superior
sensitivity compared to T2- and fluid-
attenuated-inversion-recovery (FLAIR)
sequences improved this situation, but
post-mortem comparison showed that
80% of lesions still remain undetected
(20, 21). Interestingly, MRI-visible cortical
lesions do not differ from MRI-invisible
lesions in their pathological profiles (20).
Combination with other sequences such
as phase-sensitive inversion recovery and
T1-weighted 3D-spoiled gradient-recalled
echo and ultra-high-field scanners might
help to partly overcome these problems
(20, 22), but this approach is not realizable
in clinical settings. Importantly, despite
representing the commonest lesion type,
subpial cortical lesions largely escape detec-
tion by MRI (20). Deep GM pathology is
somewhat easier to depict than cortical
GM pathology as lesions in deep GM
structures, spinal cord, and hippocampus
are generally mixed GM/WM lesions and
slightly more inflammatory (21).
DIFFUSE GRAY MATTER DAMAGE
Cortical thickness is reduced in MS (23)
and a mean cortical thinning of 10%
has been found independently of corti-
cal lesions, suggesting mechanisms besides
cortical demyelination contribute to corti-
cal atrophy (21). A recent study combining
post-mortem imaging and histopathology
to explore the underpinnings of cortical
atrophy identified neuronal density, neu-
ronal size, and axonal density as predictors
of cortical GM volume in long-standing
MS (24). GM constitutes about 65% of
brain parenchymal tissue, and atrophy of
GM largely drives whole-brain atrophy in
MS (20). GM atrophy in MS occurs both
at global and regional level and can be
quantitated using MRI. It also does not
directly correlate with the number of WM
lesions and diffuse NAWM damage, sug-
gesting partially independent pathological
processes (22). Unfortunately, GM volume
measures are inherently non-specific and
reveal little about the exact cause of tissue
injury (20).
NON-CONVENTIONAL MRI TO QUANTIFY
GRAY MATTER DAMAGE
Analogous to but less frequent than respec-
tive WM studies, DWI/DTI and MTI have
also been used to quantify GM damage in
MS. Consistent with differences in pathol-
ogy, DTI detected higher MD and FA in
cortical lesions than in WM lesions of MS
patients (22). New approaches to study
cortical MTR changes include segmenta-
tion of the cortex to obtain separate infor-
mation on outer and inner bands, where
the lowest outer cortical MTR was seen in
secondary progressive MS, consistent with
post-mortem findings of more extensive
subpial pathology in this group (25).
STRATEGIC LOCATION OF GRAY MATTER
DAMAGE
Extensive GM involvement has been associ-
ated with cognitive decline, motor deficits,
fatigue, painful syndromes, and ocular
motility disturbances in MS. In this respect,
the thalamus has been highlighted, as it
relays sensory information to higher corti-
cal centers that influence cognition (26). A
strategic significance has also been demon-
strated for the hippocampus, as lesions in
this area strongly correlate with impaired
visuospatial memory and processing speed
(20, 21). Further, using LPMs of DIR
images, cortical MS lesions have been
demonstrated to be mainly distributed in
the frontal and temporal lobes, with promi-
nent involvement of motor and anterior
cingulate cortices (27).
CONTRIBUTION OF WHITE AND GRAY
MATTER DAMAGE TO EXPLAINING
CLINICAL DEFICITS
All the above techniques have greatly
enhanced our understanding of the com-
plexity of MS tissue damage and provide
possibilities to assess the structural changes
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associated with MS in ever more detail.
At group level, several discussed metrics
alone or in combination have shown good
correlation with measures of disability or
cognition [e.g., Ref. (28)] and even sim-
ple MRI markers appear to be an excel-
lent surrogate for treatment response (29).
However, these complex insights have not
transformed into a sufficient capacity to
explain or even predict a patient’s function-
ing and clinical deficits, and are far from
having reached utility in daily clinical prac-
tice. We suggest that the reasons for this
are not only the complexity of MS-related
damage – which is certainly even much
greater than addressed above (e.g., consider
the role of other CNS compartments such
as the spinal cord) – but rather the individ-
ual variability in processes of plasticity and
adaptation.
FUNCTIONAL MRI AS ONE APPROACH
TO GAIN FUNCTIONAL INFORMATION
Functional MRI studies of visual, cognitive,
and motor systems consistently demon-
strated functional changes in all MS pheno-
types, characterized by altered activation of
regions normally devoted to performance
of a task or recruitment of additional areas
compared to healthy subjects (3, 22, 30,
31). Given the correlation between func-
tional and structural abnormalities (30),
the former appear to partly limit the func-
tional consequences of structural damage
in MS. fMRI abnormalities already occur
in CIS, but differences in activation pat-
terns between phenotypes are striking (32,
33), suggesting profound changes in the
functional organization of the MS brain
with disease progression. Final exhaustion
of adaptive capacity may constitute one
key factor for unfavorable clinical evo-
lution or cognitive decline, although the
decisive factors driving transition from
adaption to maladaptation are unknown.
However, maladaptation in MS is not only
the consequence of the final exhaustion
of adaptive plasticity but it may also be
expressed in early stages of the disease
as enhanced functional connectivity (34).
While patients with“long-term low disabil-
ity MS” may functionally withstand con-
siderable amounts of brain tissue damage,
others already suffer from severe disability
(35). Individual differences in brain reserve
and cognitive reserve thereby might play a
role (36–38). Combining MRI measures of
structural damage with those of abnormal
functional and structural connectivity (3)
using resting state fMRI (13, 39) appears
promising to further elucidate such rela-
tionships at group level, but this would
necessitate prospective longitudinal stud-
ies (40) with long-term follow-up, ideally
in multi-center settings (41).
CONCLUSION AND FUTURE
DIRECTIONS
Despite increasing level of detail, mor-
phological insights using MRI by nature
only allow assessment of (micro)structural
disease-related processes in MS-brains.
fMRI enabled detection of paralleling
adaptive cerebral changes, which – besides
the stage and dynamics of the disease –
most likely are also modulated by indi-
vidual differences (“functional reserve”).
Interpretations of such changes are cor-
roborated and usefully augmented by
concomitant assessment of morphologi-
cal MRI changes. Yet, measurement of
brain damage by structural MRI alone
clearly does not suffice to comprehensively
appreciate the consequences of the dis-
ease, although it is ideal for specific ques-
tions (e.g., assessment of disease activity,
remyelination, or evolution of atrophy).
To better understand mechanisms of func-
tional adaption in MS, longitudinal studies
including (micro)structural and functional
MRI in large registries of early MS fol-
lowed for many years are needed. Whether
this will finally allow judging capacity for
adaption at the individual level remains
unclear.
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